Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials.

ABSTRACT:

Objective

Clinical trials of therapies for lupus nephritis have used many different primary outcome measures, ranging from complete response to time to end-stage renal disease. The objective of this study was to compare several possible outcome measures, using data from a large, multicenter trial of abatacept in lupus nephritis, to gain insight into which outcome measure, if any, was best able to discern differences among treatment groups.

Methods

Study patients received either abatacept or placebo, on a background of mycophenolate mofetil and glucocorticoids. Using data from this trial, the following primary outcome measures at 24 and 52 weeks were compared: complete response rate, major clinical response rate, total response rate (complete plus partial response), improveme

SUBMITTER: Wofsy D 

PROVIDER: S-EPMC4398144 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature